» Articles » PMID: 26861277

Design of Potent and Controllable Anticoagulants Using DNA Aptamers and Nanostructures

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2016 Feb 11
PMID 26861277
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

The regulation of thrombin activity offers an opportunity to regulate blood clotting because of the central role played by this molecule in the coagulation cascade. Thrombin-binding DNA aptamers have been used to inhibit thrombin activity. In the past, to address the low efficacy reported for these aptamers during clinical trials, multiple aptamers have been linked using DNA nanostructures. Here, we modify that strategy by linking multiple copies of various thrombin-binding aptamers using DNA weave tiles. The resulting constructs have very high anticoagulant activity in functional assays owing to their improved cooperative binding affinity to thrombin due to optimized spacing, orientation, and the high local concentration of aptamers. We also report the results of molecular dynamics simulations to gain insight into the solution conformations of the tiles. Moreover, by using DNA strand displacement, we were able to turn the coagulation cascade off and on as desired, thereby enabling significantly better control over blood coagulation.

Citing Articles

A functional RNA-origami as direct thrombin inhibitor with fast-acting and specific single-molecule reversal agents in vivo model.

Krissanaprasit A, Mihalko E, Meinhold K, Simpson A, Sollinger J, Pandit S Mol Ther. 2024; 32(7):2286-2298.

PMID: 38720458 PMC: 11286819. DOI: 10.1016/j.ymthe.2024.05.002.


Design and Prediction of Aptamers Assisted by In Silico Methods.

Lee S, Cho J, Lee B, Hwang D, Park J Biomedicines. 2023; 11(2).

PMID: 36830893 PMC: 9953197. DOI: 10.3390/biomedicines11020356.


In Silico Approaches for the Identification of Aptamer Binding Interactions to spp. Cell Surface Proteins.

Almazar C, Mendoza M, Rivera W Trop Med Infect Dis. 2023; 8(2).

PMID: 36828542 PMC: 9963831. DOI: 10.3390/tropicalmed8020125.


Synthesizing the biochemical and semiconductor worlds: .

Majikes J, Liddle J Nanoscale. 2022; 14(42):15586-15595.

PMID: 36268635 PMC: 10949957. DOI: 10.1039/d2nr04040a.


A DNA origami-based aptamer nanoarray for potent and reversible anticoagulation in hemodialysis.

Zhao S, Tian R, Wu J, Liu S, Wang Y, Wen M Nat Commun. 2021; 12(1):358.

PMID: 33441565 PMC: 7807036. DOI: 10.1038/s41467-020-20638-7.


References
1.
White R, Sullenger B, Rusconi C . Developing aptamers into therapeutics. J Clin Invest. 2000; 106(8):929-34. PMC: 314350. DOI: 10.1172/JCI11325. View

2.
Baker N, Sept D, Joseph S, Holst M, McCammon J . Electrostatics of nanosystems: application to microtubules and the ribosome. Proc Natl Acad Sci U S A. 2001; 98(18):10037-41. PMC: 56910. DOI: 10.1073/pnas.181342398. View

3.
Rusconi C, Scardino E, Layzer J, Pitoc G, Ortel T, Monroe D . RNA aptamers as reversible antagonists of coagulation factor IXa. Nature. 2002; 419(6902):90-4. DOI: 10.1038/nature00963. View

4.
Di Cera E . Thrombin interactions. Chest. 2003; 124(3 Suppl):11S-7S. DOI: 10.1378/chest.124.3_suppl.11s. View

5.
Santulli-Marotto S, Nair S, Rusconi C, Sullenger B, Gilboa E . Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity. Cancer Res. 2003; 63(21):7483-9. View